This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis Gets Approval for Psoriasis Drug Cosentyx in China
by Zacks Equity Research
Novartis' (NVS) psoriasis drug gets approval in China. The company also signs an agreement to expand its biologics therapy manufacturing capability.
Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe
by Zacks Equity Research
Teva's (TEVA) CGRP injection, Ajovy gets marketing approval in the EU after securing approval in the United States last year.
Novartis (NVS) to Acquire Subsidiary of IFM Therapeutics
by Zacks Equity Research
Novartis (NVS) is set to acquire IFM Tre, a subsidiary of IFM Therapeutics LLC, and strengthen its pipeline of drugs for chronic inflammatory disorders.
Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals
by Zacks Equity Research
AstraZeneca announces a $6.9 billion cancer deal with Daiichi Sankyo. AbbVie (ABBV), Novartis (NVS) & AstraZeneca's (AZN) drugs get regulatory approvals.
NASH Scorecard So Far This Year: A Look at the Hits & Misses
by Ekta Bagri
NASH is a highly lucrative market with blockbuster potential. Let us take a look at the winners and losers in this space so far in 2019.
Global Blood Focuses on Developing Lead Candidate Voxelotor
by Zacks Equity Research
Global Blood (GBT) is fast progressing on the development plans for its lead pipeline candidate, voxelotor for the treatment of sickle cell disease.
Aerie (AERI) Improves 22% YTD: Is Momentum Likely to Sustain?
by Zacks Equity Research
Aerie (AERI) gains momentum on the back of the FDA approval of its second drug, Rocklatan.
Achillion Completes Enrollment in Rare Blood Disorder Study
by Zacks Equity Research
Achillion (ACHN) achieves enrollment target in a mid-stage study evaluating its lead candidate, ACH-4471, in paroxysmal nocturnal hemoglobinuria, a rare life-threatening disease of the blood.
Novartis (NVS) Receives FDA Approval for MS Drug Mayzent
by Zacks Equity Research
Novartis (NVS) obtains FDA approval for Mayzent for the treatment of relapsing forms of MS.
Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) announced positive top-line data from its phase III study on low sodium formulation of Xyrem, JZP-258.
Conatus (CNAT) Declines on Failure of NASH Fibrosis Study
by Zacks Equity Research
Conatus' (CNAT) stock plunges as the phase IIb study on emricasan for the treatment of biopsy-confirmed NASH and liver fibrosis fails.
Biogen Stock Crashes on Termination of Alzheimer's Studies
by Zacks Equity Research
Biogen (BIIB) and its Japanese partner, Eisai discontinue two late-stage studies evaluating aducanumab, in patients with Alzheimer's disease.
Cooper Companies' (COO) CooperVision Gains Momentum Globally
by Zacks Equity Research
Cooper Companies (COO) maintains its leading position in the markets of specialty lenses, supported by highly exclusive products like Biofinity and Clariti.
Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision
by Zacks Equity Research
The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.
Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan
by Zacks Equity Research
Conatus (CNAT) concentrates on the development of its lead candidate, emricasan, for treating patients with fibrosis or cirrhosis caused by NASH.
Tilray Earnings Impressive: More Reasons to Buy Marijuana ETFs
by Sanghamitra Saha
Tilray earnings results speak of bullishness, making things better for marijuana ETF investors.
Alnylam's (ALNY) Impressive Pipeline Drives Share Price
by Zacks Equity Research
Alnylam's (ALNY) share price increases on robust performance of pipeline candidates.
Novartis' (NVS) Alcon Acquired PowerVision for $285 Million
by Zacks Equity Research
Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.
Roche Gets Approval for Label Expansion of MabThera in Europe
by Zacks Equity Research
Roche (RHHBY) gets EC approval for the label expansion of its legacy RA drug, MabThera for pemphigus vulgaris.
Roche Receives EC Approval for Label Expansion of Hemlibra
by Zacks Equity Research
Roche (RHHBY) gets approval from European Commission for a label expansion of hemophilia drug, Hemlibra.
Allergan Announces FDA Acceptance of Migraine Candidate NDA
by Zacks Equity Research
Allergan's (AGN) new drug application seeking approval for its oral anti-CGRP candidate, ubrogepant, as acute treatment for migraine gets FDA acceptance. A decision is expected in Q4.
Roche's (RHHBY) Tecentriq Gets FDA Approval for Breast Cancer
by Zacks Equity Research
Roche (RHHBY) gets FDA approval for immuno-oncology drug, Tecentriq in combination with Abraxane for the treatment of breast cancer.
Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus
by Zacks Equity Research
Conatus (CNAT) makes an improvement with narrower-than-expected loss in the fourth quarter of 2018. Also, revenues beat mark.
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
by Zacks Equity Research
Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
by Zacks Equity Research
Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.